

Practical information

Venue	Symposium	Lecture Hall O 2 Building, De Boelelaan 1108, 1081 HZ Amsterdam
	Thesis	Aula VU, De Boelelaan 1105, 1081 HV Amsterdam
Accreditation		Accreditation has been applied for NVR, MDL, NVKC, NIV, VSR and V&VN
Registration fee		There is no registration fee
Information		Sickmann Congres Organisatie Erik Sickmann 06 - 4569 3847 info@sickco.nl

Privacy statement Sickmann Congres Organisatie gaat zorgvuldig om met uw gegevens. Door inzending stemt u in met verwerking en/of gebruik van de door u verstrekte gegevens. Sickmann Congres Organisatie gebruikt de informatie o.a. om u te voorzien van informatie over onze diensten of producten waarvan wij menen dat die voor u interessant kunnen zijn. U kunt te allen tijde uw gegevens opvragen en verzoeken ze te laten corrigeren of verwijderen. Stuur u een e-mail naar info@sickco.nl.



Please register by scanning the QR-code

INVITATION

Methotrexate cellular pharmacology and TDM in RA and inflammatory diseases: from bench to clinic

in honour of farewell dr. G. Jansen and thesis defense drs. I.B. Muller



Wednesday October 18, Lecture Hall O|2 Building,
De Boelelaan 1108, 1081 HZ Amsterdam

Methotrexate cellular pharmacology and TDM in RA and inflammatory diseases: from bench to clinic

in honour of farewell dr. G. Jansen and thesis defense drs. I.B. Muller

Dear colleague,

For decades, the antifolate drug methotrexate (MTX) has a prominent place in the treatment of immune-mediated inflammatory diseases (IMiDs), including rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, inflammatory bowel disease (Crohn's and ulcerative colitis) and dermatitis. In RA, MTX is used as single agent and in combination with biological and non-biological disease modifying anti-rheumatic drugs. Unfortunately, approximately 40% of RA patients show insufficient clinical improvement on MTX-therapy. To this end, therapeutic drug monitoring (TDM) of MTX may be a helpful tool to determine levels of therapeutically-active MTX metabolites (i.e. MTX-polyglutamates; MTX-PGs) in relation to MTX (non)-response and or toxicity. Thus far, TDM for MTX-PGs includes red blood cells. Recently, modern analytical techniques (e.g. mass spectrometry) enabled MTX-PG analysis in immune target cells relevant for disease pathogenesis.

This symposium will cover updates on MTX mechanism of action focusing on the enzyme folylpolyglutamate synthetase (FPGS) catalyzing MTX-PG formation. Positioning of MTX and biologicals will be discussed in current RA therapies. MTX-TDM approaches along with PK and PD analysis will be presented in RA and IBD disease setting. Lastly, safety and fertility aspects will be discussed based on MTX-PG analysis in spermatozoa of RA patients.

MTX-TDM could be helpful for precision medicine approaches aiming to maximize drug efficacy and minimize toxicity.

After the symposium Drs Ittai Muller will defend his thesis in the Aula of the VU. We look forward to welcoming you to the symposium in Wednesday October 18th in Amsterdam.

Chairs: Prof. dr. R. de Jonge (Head Department of Clinical Chemistry, Amsterdam UMC)
Prof. dr. J. Cloos (Research head Department of Hematology, Amsterdam UMC)
Dr. G. Jansen (Researcher Department of Rheumatology and Clinical Immunology, Amsterdam UMC)

Program

- 09.30 - 10.00 Registration, coffee/tea
- 10.00 - 10.15 Welcome address [prof. dr. R. de Jonge & prof. dr. J. Cloos]
- 10.15 - 10.50 *Prof. dr. Y.G. Assaraf (The Technion, Israel Institute of Technology, Haifa, Israel)*
Introduction Folate/MTX metabolism & FPGS
- 10.50 - 11.25 *Prof. dr. R.F. van Vollenhoven (Head department of Rheumatology and Clinical Immunology, Amsterdam UMC)*
MTX in RA clinical practice: the NORDSTAR study
- 11.25 - 11.50 *Dr. M. Bulatović Čalasan (Department of Rheumatology and Clinical Immunology, Utrecht UMC / Department of Clinical Chemistry, Amsterdam UMC)*
MTX in immune-mediated inflammatory diseases (IMiDs):
MTX pharmacokinetics (PK) and pharmacodynamics (PD)
- 11.50 - 11.55 Closing remarks by chairs
- 11.55 - 12.40 **Lunch**
- 12.40 - 13.05 *Drs. M.M. van de Meeberg (Department of Gastroenterology and Hepatology, Utrecht UMC / Department of Gastroenterology and Hepatology, Amsterdam UMC)*
MTX PK in Inflammatory Bowel Disease (IBD)
- 13.05 - 13.25 *Dr. R.C.F. Hebing (Reade Rheumatology, Amsterdam / Pharmacy Department, CWZ - Canisius-Wilhelmina Hospital, Nijmegen)*
MTX PK in RA
- 13.25 - 13.55 *Dr. G.J. Wolbink (Reade Rheumatology, Amsterdam / Sanquin, Amsterdam)*
MTX & biologicals
- 13.55 - 14.20 *Drs. L.F. Perez-Garcia (Department of Rheumatology, Erasmus MC, Rotterdam)*
MTX - RA - fertility: the iFAME-MTX study
- 14.20 - 14.30 **Concluding remarks (Dr. G. Jansen)**
- 14.45 **Transfer to VU Main Building (De Boelelaan 1105)**
- 15.45 - 16.45 Thesis defense drs. Ittai B. Muller. Location: Aula, VU Main Building
Title thesis: 'Precision medicine in rheumatoid arthritis: role of alternative splicing in methotrexate response'



Please register by scanning the QR-code